Clinical Trials Browser

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplastic Cells, Circulating, Neoplasms, Urogenital Neoplasms

NCT04106115 2024-12-04

DURANCE

Phase 1/2 Recruiting

64 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04167631 2024-10-30

Can VI-RADS/ADC Accurately Stage Bladder Cancer??

Phase NA Active not recruiting

150 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Diseases, Urinary Bladder Neoplasms

NCT06632964 2024-10-09

A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer

Phase 1 Recruiting

16 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT04593862 2024-09-19

BRAVE

Phase 2 Completed

25 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Motor Activity

NCT06588179 2024-09-19

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Phase 1/2 Not yet recruiting

58 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06187506 2024-07-12

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

Phase 2 Recruiting

20 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT06327932 2024-03-25

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer

Phase 3 Not yet recruiting

320 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

Clinical Trials

Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC

Studying the Relationship of Patient Positioning and Intravesical Bacillus Calmette Guerin Dwell Time to Improve the Treatment of Non-muscle Invasive Bladder Cancer

PLZ4-Coated Paclitaxel-Loaded Micelles for the Treatment of Patients With Recurrent or Refractory Non-Muscle Invasive Bladder Cancer

GAIN-BCG

CRUCIAL-R

Hydeal Cyst

Study of CG0070 After Transurethral Resection in Patients With IR NMIBC

A Cruciferous Vegetable Eating Program for the Reduction of Cancer Recurrence and Progression in Patients With Non-muscle Invasive Bladder Cancer

En Bloc Transurethral Resection of Non-muscle Invasive Bladder Cancer

SPICE

PERTINENCE

CUT-less

BicaBCa

TRAIN

PERSEVERANCE

NMIBC

GEMDOCE

A Study Comparing Standard Treatments in People With Non-Muscle Invasive Bladder Cancer (NMIBC)

HERO

A Study of Pemigatinib in Non-muscle Invasive Bladder Cancer Patients With Recurrent Low- or Intermediate-Risk Tumors

COBRA-NMIBC

GEM-IR-NMIBC

OHAI-NMIBC-01

In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial

Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer

A Study of RAG-01 in Patients With Non-muscle-invasive Bladder Cancer (NMIBC) Who Have Failed Bacillus Calmette Guérin (BCG) Therapy

A Study of Oral Erdafitinib in People With Recurrent Non-Invasive Bladder Cancer

Study of 2141-V11 in People With Non-muscle Invasive Bladder Cancer That Did Not Respond to Standard Treatment

RC48 in Combination With Radiotherapy for HER2-Expressing NMIBC Patients

BCG-TIME

A Study Comparing the Necessity of a Second Transurethral Resection in High-Risk Non-Muscle-Invasive Bladder Cancer Patients With Negative Results From Post-Initial Resection Urine Genome-Wide Low-Depth Sequencing

Bacillus Calmette-Guérin (BCG) and Gemcitabine in People With High-Grade Non-Muscle Invasive Bladder Cancer That Came Back After BCG Treatment

COBRA

Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial

eRapa

HIGCrecur

A Bladder-Sparing Treatment Strategies of Large-Volume Non-Muscle-Invasive Bladder Cancer

Investigating the Efficacy and Safety of Neoadjuvant Intravesical Instillation of Mitomycin C in Treating High-risk NMIBC Patients

Thulium Laser En-bloc Resection of Primary Non-muscle Invasive Bladder Cancer

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guerin on the Quality of Life in Superficial Bladder Cancer

ADAPT-BLADDER

PRIMER

CTC Quantification During TURBT and PKVBT of Transitional Cell Carcinoma in Purging Fluid and Blood

DURANCE

Can VI-RADS/ADC Accurately Stage Bladder Cancer??

A Clinical Trial Aimed At Assessing the Efficacy and Safety of VT-101 for the Treatment of Non-muscle Invasive Bladder Cancer

BRAVE

SHR-1501 Combined With SHR-2005 for High-Risk Non-Muscle Invasive Bladder Cancer Which is Not Completely Resectable by TURBt

Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer

HIVEC in Patients With Non-Muscle-Invasive Bladder Cancer